Kelly Dooley, MD

Role: 
Faculty
Associate Professor of Medicine, Pharmacology, and Molecular Sciences
Kelly Dooley, MD

Dr. Dooley is an Associate Professor of Medicine, Pharmacology, and Molecular Sciences at Johns Hopkins University School of Medicine, with appointments in the Divisions of Clinical Pharmacology and Infectious Diseases. She is also a faculty member at the Center for Clinical Global Health Education.

Dr. Dooley has an HIV outpatient practice and attends on the inpatient HIV service. Her research focuses on tuberculosis therapeutics with an emphasis on Phase I or II clinical trials of new or existing TB drugs and treatment of HIV/TB co-infection. She is Principal Investigator or Protocol Chair for several clinical trials involving TB drugs for drug-sensitive TB or drug-resistant TB and involved in the scientific committees of the Tuberculosis Trials Consortium, AIDS Clinical Trials Group, and IMPAACT networks. She has a special interest in optimizing TB drugs for special populations, including children and pregnant women.>

Dr. Dooley received her MD from Duke University, and completed residency training in internal medicine and an infectious diseases fellowship at Johns Hopkins School of Medicine. She is board certified in internal medicine and infectious diseases.

MDR-TB Free: Monitoring Adverse Effects, Utilizing Resources Optimally, Knowing Resistance Patterns, and Treatment Strategy

Post Date: 
2017-03-24
Country: 
Purpose: To establish an observational cohort of MDR-TB cases and household contacts with accompanying biorepository at PD Hinduja National Hospital and Medical Research Centre Primary Objectives: Cohort A: To document participant outcomes including early treatment response, MDR-TB treatment-...

Measuring TB Drugs in Hair as a Tool to Monitor Adherence, Exposure and Response in Patients with HIV

Post Date: 
2016-08-16
Country: 
Our study will examine whether hair levels of two key first line tuberculosis drugs will be useful markers to identify individuals at highest risk of treatment failure in active tuberculosis. Our study aims to provide a lowcost clinical tool using hair that can be noninvasively collected to monitor...

TBM Kids Substudy: Assessment of Neurocognitive Functions in Children with Tuberculosis Meningitis and Healthy Control Children Using the Mullen Scale of Early Learning Attending a Tertiary Care Public Hospital in Pune, India

Post Date: 
2014-09-01
Country: 
Objectives: The aim of the present study is to examine the neurological deficit in TBM kids and for that we need to assess, feasibility of the MSEL in our set up an Indian population of healthy children and children with meningitis in particular TB meningitis(TBM). The primary objective of the...

Optimizing Treatment to Improve TBM Outcomes in Children

Post Date: 
2014-05-01
Country: 
This study is being conducted in India and Malawi. Primary Objectives To characterize the pharmacokinetics (PK) (plasma and cerebrospinal fluid (CSF)) of rifampicin given at model-derived optimal daily doses and levofloxacin in children ages 6 months to 12 years of age with TBM To assess the...

BWI CTU: Baltimore-Washington-India Clinical Trials Unit

Post Date: 
2007-02-02
Comprising clinical trial sites at Johns Hopkins Medicine in Baltimore, Whitman Walker Health in Washington, DC, and the BJGMC-CCGHE collaboration in Pune, India, the Baltimore-Washington-India Clinical Trials Unit (BWI-CTU) is one of only 25 international HIV/TB clinical trial sites funded by the...

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

Post Date: 
2017-03-24
Publication: 
The Lancet Respiratory Medicine
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tuberculosis control has been effective in some regions of the world, these gains are threatened by the increasing...

Tuberculosis associated with HIV infection

Post Date: 
2017-01-15
Publication: 
Microbiology Spectrum
Abstract Tuberculosis (TB) has recently surpassed HIV as the primary infectious disease killer worldwide, but the two diseases continue to display lethal synergy. The burden of TB is disproportionately borne by people living with HIV, particularly where HIV and poverty coexist. The impact of these...

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study

Post Date: 
2016-06-01
Publication: 
International Journal of Tuberculosis and Lung Disease
Country: 
Assessing treatment adherence and quantifying exposure to anti-tuberculosis drugs among children is challenging. We undertook a 'proof of concept' study to assess the drug concentrations of isoniazid (INH) in hair as a therapeutic drug monitoring tool. Children aged <12 years initiated on a...

Toward earlier inclusion of pregnant and postpartum women in TB drug trials: consensus statements from an International Expert Panel

Post Date: 
2016-01-04
Publication: 
Clinical Infectious Diseases
Tuberculosis is a major cause of morbidity and mortality in women of childbearing age (15–44 years). Despite increased tuberculosis risk during pregnancy, optimal clinical treatment remains unclear: safety, tolerability, and pharmacokinetic data for many tuberculosis drugs are lacking, and trials...

Pediatric tuberculous meningitis: model-based approach to determining optimal doses of anti-tuberculosis drugs for children

Post Date: 
2015-10-22
Publication: 
Clinical Pharmacology and Therapeutics
Pediatric tuberculous meningitis (TBM) is a highly morbid, often fatal disease. Standard treatment includes isoniazid, rifampin, pyrazinamide, and ethambutol. Current rifampin dosing achieves low cerebrospinal fluid (CSF) concentrations, and CSF penetration of ethambutol is poor. In adult trials,...

Safety, tolerability, and pharmacokinetic interactions between single-dose TMC207 and steady-state efavirenz in healthy volunteers: AIDS Clinical Trials Group (ACTG) Study.

Post Date: 
2012-04-15
Publication: 
Journal of Acquired Immune Deficiency Syndromes
Country: 
Background: Drug-drug interactions complicate management of coinfection with HIV-1 and Mycobacterium tuberculosis. Bedaquiline (formerly TMC207), an investigational agent for the treatment of tuberculosis, is metabolized by cytochrome P450 (CYP) 3A which may be induced by the antiretroviral drug...

Sub-Therapeutic Concentrations of Anti-Tuberculosis Drugs in Children when Treated According to Indian Dosing Recommendation

Post Date: 
2016-10-24
Presentation Location: 
Liverpool, England
Country: 
Event & Convener: 
9th Annual International Workshop on Clinical Pharmacology of Tuberculosis Drugs
Oral Presentation. Guiastrennec B , Ramachandran G, Karlsson MO, Kumar H, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM.

Isoniazid Hair Concentrations in Children with TB

Post Date: 
2015-12-05
Presentation Location: 
Cape Town, South Africa
Country: 
Event & Convener: 
46th Union World Conference on Lung Health. International Union for Tuberculosis and Lung Disease.
Poster Session. Authors: Mave V, Kinikar AA, Gupte N, Nimkar S, Kagal A, Horng H, Ramachandran G, Dooley K, Gupta A.

TB/HIV Treatment during Pregnancy: Does Drug Metabolism Change?

Post Date: 
2015-12-04
Presentation Location: 
Cape Town, South Africa
Event & Convener: 
The 46th Union World Conference on Lung Health
Symposium. Maternal and Infant TB: Advancing Our Understanding of Pathogenesis, Treatment and Prevention. Dooley K, Savic R.